Home > Lower-risk Myelodysplastic Syndrome > Efficacy > Liver Iron Concentration

In this section:

Liver iron Concentration

In transfusion-dependent, lower-risk MDS

EXJADE Reduces the Burden of Iron Toxicity on the Liver

EXJADE removes hepatic iron

Reduction in Mean LIC1,2
EXJADE® Removes Hepatic Iron in MDS Patients

Data from a prospective analysis of 24 patients with low and intermediate-1–risk myelodysplastic syndrome with evidence of iron toxicity who received treatment with EXJADE. Nine patients completed 1 year of therapy.1

In another study

  • 79% success rate in reducing liver iron concentration across the dose range3
Learn more about this study

EXJADE REDUCES SERUM FERRITIN AND THE BURDEN OF IRON TOXICITY

EXJADE clinical studies show reductions in serum ferritin.

Learn more

EXJADE SAFETY PROFILE ACROSS ANEMIAS

Learn more